LivaNova (LIVN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$81.92+0.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · LIVN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 12.2% |
| Our one-year growth estimate | diamond | 8.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
LIVN — President transition
Dated 2026-01-14
Chief Legal Officer — Michael Hutchinson: The Chief Legal Officer is resigning to pursue another opportunity, which is a standard executive departure without indication of cause or distress.
Why it matters: FDA approvals can help LivaNova grow. They can offer more products and reach more markets.
Supportive ifAnnouncement of FDA approval for a new product in Q3.
Worry ifNo new FDA approvals are announced in Q3.
Why it matters: Confirming the revenue growth guidance of 8-9% shows strong demand and execution.
Supportive ifFull-year 2026 revenue growth lands within the 8-9% range on a constant-currency basis.
Worry ifRevenue growth falls below 8% on a constant-currency basis.
Why it matters: Progress on this deal could improve LivaNova's supply chain and production. This may affect growth.
Supportive ifManagement says the Thermo Fisher deal has started or is growing.
Worry ifManagement reports delays or problems with the Thermo Fisher deal.
Why it matters: FDA updates can signal progress in the obstructive sleep apnea market, a key growth area.
Supportive ifFDA approved more uses for the aura6000 System.
Worry ifNo new FDA approvals or negative feedback on the aura6000 System.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$124 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $318 loss on $10,000 · 3.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,889 loss on $10,000 · 18.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New approvals would strengthen LivaNova's place in the growing sleep apnea market.
Supportive ifFDA approves new devices for obstructive sleep apnea.
Worry ifNo new FDA approvals for OSA devices in the next quarter.
Why it matters: Higher EPS guidance would show better profits. It may make investors feel more positive.
Supportive ifIf adjusted EPS guidance goes above $4.30, it would show better earnings ahead.
Worry ifGuidance remains at or below $4.30.
Why it matters: If revenue growth falls below the median, it could signal a slowdown in LivaNova's business. This would be a concern for investors.
Worry ifLivaNova reports revenue growth below the sector median of 1% year over year.
Less concerning ifLivaNova reports revenue growth above the sector median of 1% year over year.
Why it matters: This would show slower growth. It could hurt investor trust in LivaNova's 2026 goals.
Worry ifQ2 revenue growth below 7% year over year would confirm a slowdown.
Less concerning ifQ2 revenue growth meets or exceeds 7% year over year.
Why it matters: The Q2 results will show if LivaNova's financial health is improving or not. Investors will look for signs of recovery or continued losses.
Watch forEarnings report shows revenue growth year over year of at least 5%.
Also watch forEarnings report shows revenue decline year over year of more than -5%.
Why it matters: Meeting or exceeding this growth target confirms strong momentum in LivaNova's core businesses. It shows that management's guidance is on track.
Supportive ifQ3 revenue growth of 8% or more compared to Q3 2025.
Worry ifQ3 revenue growth falls below 8% year-over-year.
Why it matters: Hitting this EPS target shows LivaNova is making money and growing. It shows strong operations.
Supportive ifAdjusted diluted EPS for 2026 reaches $4.30 or higher.
Worry ifAdjusted diluted EPS for 2026 falls below $4.30.
Why it matters: Staying in this cash flow range shows LivaNova can handle investments and make cash. This is key for growth.
Worry ifAdjusted free cash flow for 2026 is reported between $140 million and $160 million.
Less concerning ifAdjusted free cash flow falls below $140 million.
Why it matters: Updates on this supply chain deal will show if LivaNova can meet oxygenator demand. It will also show if they can make more.
Watch forNews about more oxygenator production. Better supply chain results come from the deal.
Also watch forNo news or delays in starting the agreement.